AngioDynamics, Inc.

Equities

ANGO

US03475V1017

Medical Equipment, Supplies & Distribution

Market Closed - Nasdaq Other stock markets 04:00:00 2024-06-28 pm EDT			5-day change	1st Jan Change
6.05 ^USD	+2.02%		+2.89%	-22.83%

May. 21	AngioDynamics Obtains CE Mark Approval in Europe for AlphaVac F18 System	MT
May. 06	AngioDynamics, Inc. Announces Results from the Acute Pulmonary Embolism Extraction Trial with the Alphavac System (APEX-AV)	CI

Tranche Update on AngioDynamics, Inc.'s Equity Buyback Plan announced on November 9, 2016.

January 05, 2018 at 03:35 pm EST

From September 1, 2017 to November 30, 2017, the company has repurchased 0 shares, representing 0% for $0 million. With this, the company has completed the repurchase of 870,000 shares, representing 2.37% for $13.54 million under the buyback announced on November 9, 2016.

Latest news about AngioDynamics, Inc.

AngioDynamics Obtains CE Mark Approval in Europe for AlphaVac F18 System	May. 21	MT
AngioDynamics, Inc. Announces Results from the Acute Pulmonary Embolism Extraction Trial with the Alphavac System (APEX-AV)	May. 06	CI
North American Morning Briefing : Inflation Data, -2-	Apr. 08	DJ
Oppenheimer Upgrades AngioDynamics to Outperform From Perform, $12 Price Target	Apr. 05	MT
AngioDynamics Shares Jump After Fiscal Q3 Results, FDA Clearance For Device	Apr. 04	MT
AngioDynamics Shares Rise 10% After FDA Clears AlphaVac F18 System	Apr. 04	DJ
Transcript : AngioDynamics, Inc., Q3 2024 Earnings Call, Apr 04, 2024	Apr. 04
AngioDynamics Gets FDA Clearance For Pulmonary Embolism Treatment	Apr. 04	DJ
Earnings Flash (ANGO) ANGIODYNAMICS Reports Q3 Revenue $66M	Apr. 04	MT
AngioDynamics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended February 29, 2024	Apr. 04	CI
AngioDynamics, Inc. Reports Consolidated Goodwill Impairment for Third Quarter Ended February 29, 2024	Apr. 04	CI
AngioDynamics, Inc. Provides Sales Guidance for the Fiscal Year 2024	Apr. 04	CI
AngioDynamics, Inc. Receives 510(k) Clearance for AlphaVac F1885 System in Treatment of PE	Apr. 04	CI
North American Morning Briefing : Focus Turns to -2-	Apr. 04	DJ
AngioDynamics Settles Patent Dispute with Becton, Dickinson Affiliate	Apr. 01	MT
AngioDynamics Settles Multi-Year Patent Dispute with Becton Dickinson & Co	Apr. 01	DJ
AngioDynamics Sells Two Product Lines to Spectrum Vascular for up to $45 Million Cash; Shares Up in Pre-Bell Trading	Feb. 16	MT
Spectrum Vascular acquired PICC and Midline Product Portfolios from AngioDynamics, Inc. for $45 million.	Feb. 14	CI
Angiodynamics, Inc. Announces Board Changes	Feb. 13	CI
AngioDynamics Receives FDA Clearance for Auryon XL Radial Access Catheter	Jan. 23	MT
Angiodynamics Announces FDA 510(K) Clearance of Auryon Xl Radial Access Catheter to Treat Peripheral Arterial Disease	Jan. 23	CI
AngioDynamics, Inc. Announces Dennis Meteny to Retire as A Member of the Board of Directors, Member of the Compensation Committee and Chair of the Audit Committee, Effective January 31, 2024	Jan. 22	CI
Transcript : AngioDynamics, Inc. Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-11-2024 09:00 AM	Jan. 11
Raymond James Adjusts Price Target on AngioDynamics to $10 From $12, Maintains Outperform Rating	Jan. 09	MT
HC Wainwright Adjusts Price Target on AngioDynamics to $18 From $20, Keeps Buy Rating	Jan. 08	MT

Chart AngioDynamics, Inc.

Duration

Period

More charts

Company Profile

AngioDynamics, Inc. is a transformative medical technology company. The Company is focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options and improving quality of life for patients. It designs, manufactures, and sells a range of medical, surgical and diagnostic devices used by professional healthcare providers for vascular access, for the treatment of peripheral vascular disease and for use in oncology and surgical settings. Its devices are generally used in minimally invasive, image-guided procedures. Its segments include Med Tech and Med Device. Its product categories include oncology, venous therapies, vascular interventions, and ports. Its oncology products include Model 1500X RF Generator, IsoLoc Endorectal Balloon, Habib 4X Laparoscopic Bipolar Resection Device, Habib 4X Bipolar Resection Device, and Alatus. Its venous therapies include VenaCure EVLT 1470 Pro Laser, VenaCure EVLT System, VenaCure EVLT Procedure Packs, and others.

Sector

Medical Equipment, Supplies & Distribution

Calendar

2024-07-09 - Q4 2024 Earnings Release (Projected)

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Ratings for AngioDynamics, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

6.05 USD

Average target price

13.5 USD

Spread / Average Target

+123.14%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Medical Equipment, Supplies & Distribution

	1st Jan change	Capi.
ANGIODYNAMICS, INC.	-22.83%	242M
ABBOTT LABORATORIES	-5.60%	181B
MEDTRONIC PLC	-4.45%	101B
BECTON, DICKINSON AND COMPANY	-4.15%	67.54B
DEXCOM, INC.	-8.63%	45.09B
CENCORA, INC.	+9.70%	44.37B
HOYA CORPORATION	+6.13%	40.7B
METTLER-TOLEDO INTERNATIONAL, INC.	+15.22%	29.85B
TERUMO CORPORATION	+14.80%	24.49B
WEST PHARMACEUTICAL SERVICES, INC.	-6.46%	23.99B

Other Medical Equipment, Supplies & Distribution